Top ▲

Bcl-2-like 1

Click here for help

Immunopharmacology Ligand  Target has curated data in GtoImmuPdb

Target id: 2845

Nomenclature: Bcl-2-like 1

Abbreviated Name: Bcl-xL

Family: B-cell lymphoma 2 (Bcl-2) protein family

Contents:

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 233 20q11.21 BCL2L1 BCL2 like 1
Mouse 1 233 2 H1 Bcl2l1 BCL2-like 1
Rat 1 233 3q41 Bcl2l1 Bcl2-like 1
Gene and Protein Information Comments
A shorter human isoform, Bcl-xS, is produced from transcript variant NM_001191 (170 aa). A longer mouse isoform Bcl-x gamma, is produced from transcript variant NM_001289739 (235 aa). For the rat gene we represent the isoform analoghous to the human and mouse in the table above. Note that both a longer rat isoform (284 aa) and a shorter isoform (170 aa) have been reported.
Previous and Unofficial Names Click here for help
BCL2-like 1 | Bcl-X | BCLX
Database Links Click here for help
Alphafold Q07817 (Hs), Q64373 (Mm), P53563 (Rn)
ChEMBL Target CHEMBL4625 (Hs), CHEMBL3309112 (Mm), CHEMBL1075182 (Rn)
Ensembl Gene ENSG00000171552 (Hs), ENSMUSG00000007659 (Mm), ENSRNOG00000007946 (Rn)
Entrez Gene 598 (Hs), 12048 (Mm), 24888 (Rn)
Human Protein Atlas ENSG00000171552 (Hs)
KEGG Gene hsa:598 (Hs), mmu:12048 (Mm), rno:24888 (Rn)
OMIM 600039 (Hs)
Pharos Q07817 (Hs)
RefSeq Nucleotide NM_138578 (Hs), NM_001289716 (Mm), NM_001033670 (Rn)
RefSeq Protein NP_612815 (Hs), NP_001276645 (Mm), NP_001028842 (Rn)
UniProtKB Q07817 (Hs), Q64373 (Mm), P53563 (Rn)
Wikipedia BCL2L1 (Hs)
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of Bcl-xL in complex with ABT-737.
PDB Id:  2YXJ
Ligand:  ABT-737
Resolution:  2.2Å
Species:  Human
References:  6

Download all structure-activity data for this target as a CSV file go icon to follow link

Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
APG-1252-M1 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 9.9 pKi 4
⤷ pKi 9.9 (Ki 1.34x10-10 M) [4]
ABT-737 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Antagonist >9.3 pKi 1
⤷ pKi >9.3 (Ki <5x10-10 M) [1]
lisaftoclax Small molecule or natural product Click here for species-specific activity table Hs Antagonist >9.3 pKi 7
⤷ pKi >9.3 (Ki <5x10-10 M) [7]
navitoclax Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist >9.0 pKi 8
⤷ pKi >9.0 (Ki <1x10-9 M) [8]
venetoclax Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Antagonist 7.3 pKi 9
⤷ pKi 7.3 (Ki 4.8x10-8 M) [9]
obatoclax Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Antagonist 5.3 pKi 10
⤷ pKi 5.3 (Ki 4.69x10-6 M) [10]
Description: In vitro antagonism determined in a fluorescence polarisation assay.
A-1331852 Small molecule or natural product Hs Antagonist 8.2 pEC50 5
⤷ pEC50 8.2 (EC50 6.3x10-9 M) [5]
Description: MOLT-4 cell viability assay.
AZD4320 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 9.0 pIC50 3
⤷ pIC50 9.0 (IC50 1x10-9 M) [3]
foselutoclax Small molecule or natural product Hs Antagonist - - 2
⤷ [2]
Immunopharmacology Comments
The role of Bcl-2 family members in immunity and disease is reviewed in [5]. Pharmacological inhibition of Bcl-2 family proteins reduces disease severity in several animal models of autoimmunity; see ligand ABT-737 [1].
Immuno Process Associations
Immuno Process:  Cytokine production & signalling
Immuno Process:  Antigen presentation

References

Show »

1. Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, Martineau D, McClellan WJ, Mitten M, Ng SC et al.. (2007) Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem, 50 (4): 641-62. [PMID:17256834]

2. Crespo-Garcia S, Fournier F, Diaz-Marin R, Klier S, Ragusa D, Masaki L, Cagnone G, Blot G, Hafiane I, Dejda A et al.. (2024) Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results. Nat Med, 30 (2): 443-454. [PMID:38321220]

3. Diebold RB, Gero TW, Grover P, Huang S, Ioannidis S, Ogoe CA, Saeh JC. (2016) Chemical compounds. Patent number: US9248140B2. Assignee: AstraZeneca AB. Priority date: 06/08/2010. Publication date: 02/02/2016.

4. Hopkins J, Tsuruda P, Chapman C, Sweigard H, Poon Y, Marquess D, David N, Dananberd J, Laberg RM. (2019) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells. Patent number: WO2019033119A1. Assignee: Unity Biotechnology, Inc., Buck Institute For Research On Aging. Priority date: 13/08/2018. Publication date: 14/02/2019.

5. Le Wang, George A. Doherty, Andrew S. Judd*, Zhi-Fu Tao, T. Matthew Hansen, Robin R. Frey, Xiaohong Song, Milan Bruncko, Aaron R. Kunzer, Xilu Wang, Michael D. Wendt, John A. Flygare, Nathaniel D. Catron, Russell A. Judge, Chang H. Park, Shashank Shekhar, Darren C. Phillips, Paul Nimmer, Morey L. Smith, Stephen K. Tahir, Yu Xiao, John Xue John Xue AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States More by John Xue , Haichao Zhang, Phuong N. Le, Michael J. Mitten, Erwin R. Boghaert, Wenqing Gao, Peter Kovar, Edna F. Choo, Dolores Diaz, Wayne J. Fairbrother, Steven W. Elmore, Deepak Sampath, Joel D. Leverson, and Andrew James Souers. (2020) Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor. ACS Med Chem Lett, [Epub ahead of print]. DOI: 10.1021/acsmedchemlett.9b00568

6. Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, Colman PM, Fairlie WD. (2007) Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ, 14 (9): 1711-3. [PMID:17572662]

7. Luo Q, Pan W, Zhou S, Wang G, Yi H, Zhang L, Yan X, Yuan L, Liu Z, Wang J et al.. (2020) A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma. Oncol Res, 28 (4): 331-344. [PMID:32093809]

8. Park CM, Bruncko M, Adickes J, Bauch J, Ding H, Kunzer A, Marsh KC, Nimmer P, Shoemaker AR, Song X et al.. (2008) Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem, 51 (21): 6902-15. [PMID:18841882]

9. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ et al.. (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med, 19 (2): 202-8. [PMID:23291630]

10. Wan Y, Dai N, Tang Z, Fang H. (2018) Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents. Eur J Med Chem, 146: 471-482. [PMID:29407973]

How to cite this page

B-cell lymphoma 2 (Bcl-2) protein family: Bcl-2-like 1. Last modified on 20/05/2024. Accessed on 08/10/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2845.